Zogenix Launches Global Program to Boost Access to Fintepla

Zogenix Launches Global Program to Boost Access to Fintepla

294000

Zogenix Launches Global Program to Boost Access to Fintepla

Zogenix has launched a global access program for Fintepla (fenfluramine) to make the medication available to more patients with Dravet syndrome. In the United States and the European Union, Fintepla is approved as an add-on treatment to help prevent seizures in people with Dravet syndrome, ages 2 and up. According to Zogenix, the new expanded access program will give physicians in other parts of the world — including parts of Europe where reimbursement has not…

You must be logged in to read/download the full post.